Reviewing Cingulate (NASDAQ:CING) and Qiagen (NYSE:QGEN)

Cingulate (NASDAQ:CING) and Qiagen (NYSE:QGEN) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, profitability, valuation, earnings and risk.

Profitability

This table compares Cingulate and Qiagen’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Cingulate	N/A	-509.72%	-172.37%
Qiagen	20.33%	14.56%	8.62%

Analyst Ratings

This is a breakdown of current ratings for Cingulate and Qiagen, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cingulate	1	0	2	0	2.33
Qiagen	0	7	4	1	2.50

Cingulate currently has a consensus price target of $34.50, suggesting a potential upside of 542.46%. Qiagen has a consensus price target of $47.09, suggesting a potential upside of 37.54%. Given Cingulate’s higher probable upside, equities research analysts clearly believe Cingulate is more favorable than Qiagen.

Valuation and Earnings

This table compares Cingulate and Qiagen”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cingulate	N/A	N/A	-$22.45 million	($4.32)	-1.24
Qiagen	$2.09 billion	3.38	$424.88 million	$2.02	16.95

Qiagen has higher revenue and earnings than Cingulate. Cingulate is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

41.3% of Cingulate shares are held by institutional investors. Comparatively, 70.0% of Qiagen shares are held by institutional investors. 4.3% of Cingulate shares are held by insiders. Comparatively, 9.0% of Qiagen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility and Risk

Cingulate has a beta of -0.81, meaning that its stock price is 181% less volatile than the S&P 500. Comparatively, Qiagen has a beta of 0.65, meaning that its stock price is 35% less volatile than the S&P 500.

Summary

Qiagen beats Cingulate on 13 of the 14 factors compared between the two stocks.

About Cingulate

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

About Qiagen

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. The firm assay technologies make these biomolecules visible and ready for analysis. Its bioinformatics software and knowledge bases interpret data to report relevant, actionable insights. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996, and is headquartered in Venlo, the Netherlands.